Cargando…
Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials
BACKGROUND: Numerous studies have evidenced that statins can reduce the incidence of cardiovascular disease. However, the effects of high-dose rosuvastatin (RSV) preloading in patients undergoing percutaneous coronary intervention (PCI) are controversial. OBJECTIVE: We attempted to identify and quan...
Autores principales: | Pan, Yilong, Tan, Yuan, Li, Bin, Li, Xiaodong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549857/ https://www.ncbi.nlm.nih.gov/pubmed/26306625 http://dx.doi.org/10.1186/s12944-015-0095-1 |
Ejemplares similares
-
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2014) -
Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy
por: Yun, Kyeong Ho, et al.
Publicado: (2014) -
Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2017) -
Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention
por: Firouzi, Ata, et al.
Publicado: (2018) -
Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis
por: Sun, Jinling, et al.
Publicado: (2023)